Competent authorities should be able to access information on the safety features of a medicinal product while this product is in the supply chain or after it has been supplied to the public, recalled or withdrawn from the market.
Ces conditions devraient s'appliquer que la désactivation ait eu lieu au moment où le médicament a été délivré au public ou à une date antérieure.